08/03/22 6:00 AMNasdaq : SVA covid-19SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong KongSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that based on related clinical trials and studies of vaccination for local children and adolescents, the Health Bureau of the Government of the Hong Kong Special Administrative Region of the People’ s Republic of China has approved the Company’ s COVID-19 vaccine,...RHEA-AIneutral
07/19/22 1:30 AMNasdaq : SVA clinical trialSINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in ChileSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that a phase III clinical trial for SINOVAC’ s inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile through a collaboration with the Pontificia Universidad Católica de Chile. In total, there will be 1,600 volunteers recruited, half of...RHEA-AIneutral
07/14/22 5:10 AMNasdaq : SVA covid-19SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In BrazilSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that its COVID-19 vaccine has been approved by the Brazilian Health Regulatory Agency for emergency use in children from 3 to 5 years old on 13 July. Participants in this evaluation activity were the Brazilian Society of Pediatrics, the Brazilian Society of...RHEA-AIneutral
06/25/22 12:30 AMNasdaq : SVA covid-19SINOVAC COVID-19 Vaccine Is Conditionally Registered In South AfricaSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that the South African Health Products Regulatory Authority granted conditional registration to SINOVAC CoronaVac ® in aged 18 and above adults, based on acceptable safety, quality, and efficacy data submitted. The CoronaVac ® was previously authorized for...RHEA-AIvery positive
06/08/22 10:00 PMNasdaq : SVA SINOVAC Polio Vaccine Prequalified by WHOSINOVAC Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that it received the World Health Organization prequalification for its Poliomyelitis Vaccine on June 2, 2022. The vaccine will be available for United Nations agencies to purchase to support the global polio endgame strategy. SINOVAC's sIPV is applicable...RHEA-AIneutral
05/06/22 6:00 AMNasdaq : SVA SINOVAC Updates the Status Under Holding Foreign Companies Accountable ActSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, is aware that the Company has been identified by the United States Securities and Exchange Commission under the Holding Foreign Companies Accountable Act of the United States on May 4, 2022. Sinovac Biotech Ltd. is a China- based biopharmaceutical company that focuses on the...RHEA-AIneutral
04/29/22 6:30 PMNasdaq : SVA earningsSINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-FSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20- F with the U.S. Securities and Exchange Commission for the year ended December 31, 2021. Sales for the six months ended December 31, 2021 were $8.4 billion, compared to $442.9 million in the prior year period. Sales in 2021 were $19.4...RHEA-AIneutral
02/22/22 8:30 AMNasdaq : SVA Sinovac Amends Shareholder Rights PlanSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. SINOVAC Biotech Ltd. is a China- based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human...RHEA-AIneutral
12/30/21 4:05 PMNasdaq : SVA earningsSINOVAC Reports Unaudited First Half of 2021 Financial ResultsSinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2021. Sales for the six months ended June 30, 2021 were $11.0 billion, compared to $67.7 million in the prior year period. The Company posted $5.1 billion of net income attributable to common...RHEA-AIneutral
12/09/21 2:26 PMNasdaq : SVA Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 JudgmentSINOVAC Biotech Ltd., a leading provider of biopharmaceutical products in China, today provided an update for shareholders with regard to the exchange of preferred share purchase rights for the Company’ s Common Shares and Series B Convertible Preferred Shares, originally announced via press release on February 22, 2019. On December 19, 2018, the High Court...RHEA-AIneutral